Inactief instrument

Andere talen MannKind Corporation Nasdaq

Aandelen

US56400P2011

slotkoers Nasdaq Andere beurzen
- ^USD	-

22/06	MannKind Corporation kondigt positieve resultaten over 17 weken aan van de INHALE-3-studie	CI
29/05	MannKind gaat akkoord met wederzijdse licentieovereenkomst met Pulmatrix	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions	22/06
MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study	22/06
MannKind Corporation - Inhale-3 Study Results to be presented during a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions	06/06
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions	05/06
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	30/05
MannKind Agrees to Cross License Deal With Pulmatrix	29/05
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix	29/05
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	29/05
MannKind : First Quarter 2024 Earnings Call Presentation	09/05
MannKind: Q1 Earnings Snapshot	09/05
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	08/05
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M	08/05
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update	08/05
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment	06/05
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	06/05
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	06/05
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024	01/05
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30/04
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MannKind Corporation Nasdaq

Aandelen

US56400P2011

Andere talen

Filters